Guidelines for therapy of autoimmune liver disease

Hiromi Ishibashi, Atsumasa Komori, Shinji Shimoda, M. Eric Gershwin

研究成果: Contribution to journalReview article査読

43 被引用数 (Scopus)

抄録

The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.

本文言語英語
ページ(範囲)214-226
ページ数13
ジャーナルSeminars in Liver Disease
27
2
DOI
出版ステータス出版済み - 5 2007
外部発表はい

All Science Journal Classification (ASJC) codes

  • 肝臓学

フィンガープリント

「Guidelines for therapy of autoimmune liver disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル